@prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "\"Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). Do not co-administer aliskiren with captopril tablets in patients with diabetes (see PRECAUTIONS, Drug Interactions Captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer captopril tablet within 36 hours of switching to or from sacubitril/valsartan, a nepriltsin inhibitor ( see PRECAUTIONS, Drug Interactions\""; bl:provided_by ; bl:relation schema:MedicalContraindication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "ImzXa5p4U8QDmtSTLSd1JNHNUPKD+gzbiqX3vH5URvU3okd8s5ksrDAqKBQbwbGIHLy/cJWjhDGAogc7GUtcJH2S48Eq3r/+A0UOSZhmvz/gr6NCK6XUjBwj9mMCgah/V3EIJ0/1btTBp6/qbVmjKDK48KPhrSxKgEfpQXK5J4w="; npx:hasSignatureTarget this: . this: dct:created "2021-08-23T13:05:55.070+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }